Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells

Area of Science:

• Oncology
• Cell Therapy
• Gene Therapy

Background:

• Mesenchymal stromal cells (MSCs) have been explored as tumor-targeted delivery vehicles for over a decade.
• Key properties of tumor cells and MSCs influencing treatment efficacy have been identified.
• Critical factors for maximizing antitumor effects require careful consideration.

Purpose of the Study:

• To review the major determinants for applying prodrug-activating MSCs in antitumor therapy.
• To outline strategies for maximizing therapeutic efficiency using engineered MSCs.
• To highlight the potential of prodrug-activating MSCs for clinical applications.

Main Methods:

• Review of preclinical studies on engineered MSCs for cancer therapy.
• Analysis of critical factors influencing MSC-mediated gene-directed enzyme/prodrug therapy.
• Examination of tumor cell and MSC properties relevant to treatment outcomes.

Main Results:

• Engineered MSCs expressing activating enzymes can achieve long-term curative effects.
• This approach has shown efficacy in metastatic and difficult-to-treat cancers in preclinical models.
• Prodrug-activating MSCs represent a promising strategy for cancer treatment.

Conclusions:

• Prodrug-activating MSCs offer a potent approach for cancer therapy.
• Understanding key determinants is crucial for optimizing their clinical application.
• Further research and clinical translation of this technology are warranted.